Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2022-07-05 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2022-07-05 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Regeneron Pharmaceuticals, Inc. It reports the submission of matters to a vote of security holders at the 2022 Annual Meeting of Shareholders held on June 10, 2022. The content includes detailed voting results for election of directors, ratification of the independent auditor, and advisory vote on executive compensation. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an Annual Report, Proxy Statement, or Management Report, but specifically reports voting outcomes. The length is 4411 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2022-06-15 English
PRIMARY DOCUMENT
Director's Dealing
2022-06-03 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement, specifically an amended and restated license and collaboration agreement between Regeneron Pharmaceuticals and Sanofi Biotechnology. The document includes detailed descriptions of the agreement terms, payments, and amendments, but does not contain financial statements or quarterly/annual financial results. It is not an earnings release, annual report, or interim report. It is a regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (9811 characters) and content confirm it is not a brief announcement but a detailed regulatory filing.
2022-06-02 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing, which is a Tender Offer Statement pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It details the terms, conditions, and results of a tender offer by Regeneron Pharmaceuticals, Inc. to acquire Checkmate Pharmaceuticals, Inc. It includes information about the offer expiration, shares tendered, consummation of the merger, and delisting of shares. The document is an official filing related to a merger and acquisition transaction, specifically a tender offer and subsequent merger. It is not a general regulatory filing, earnings release, or annual report. Therefore, the appropriate classification is related to M&A activity filings, which cover merger proposals and takeover bids such as Schedule TO filings.
2022-05-31 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO Amendment No. 2 filed with the SEC related to a tender offer by Regeneron Pharmaceuticals, Inc. to purchase shares of Checkmate Pharmaceuticals, Inc. It references the Securities Exchange Act of 1934, Rule 14d-1, and Rule 14d-9, which are specific to tender offers. The document includes detailed information about the tender offer, legal proceedings related to the merger, terms of the transaction, source of funds, and other regulatory disclosures. It is not a full annual or quarterly report, nor is it a simple announcement or certification. The presence of the Schedule TO form and the detailed tender offer information clearly identifies this as a filing related to a takeover bid or merger transaction. Therefore, the appropriate classification is 'Tender Offer Statement' which falls under the M&A Activity category (Code: TAR).
2022-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.